Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Kates

Showing results (91-100 of 157) with videos related to

Pageof 16
Sort By:
Archives of Pathology & Laboratory Medicine|July 1, 2026
Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease SitesSwati Bhardwaj, Eli Morris, Aditya Halthore, et al.
Clinical Genitourinary Cancer|December 28, 2020
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective ExperienceJean Hoffman-Censits, Woonyoung Choi, Trinity J Bivalacqua, et al.
The Journal of Pathology. Clinical Research|February 19, 2025
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cellsBurles A Johnson, Vamsi Parimi, Sonia Kamanda, et al.
The Journal of Urology|May 16, 2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder CancerMax Kates, Ahmed M Mansour, Donald L Lamm, et al.
World Journal of Urology|April 29, 2019
Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumorOudai Hassan, Belkiss Murati Amador, Kara A Lombardo, et al.
The Journal of Urology|March 25, 2026
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION TrialSandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
Urology Practice|November 11, 2025
Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical TrialsCharles C Peyton, Max Kates, Anagha Nadkarni, et al.
Urologic Oncology|October 25, 2016
Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomyMeera R Chappidi, Heather J Chalfin, Daniel J Johnson, et al.
The Journal of Urology|April 29, 2026
Reply by AuthorsSandip M Prasad, Dimitar Shishkov, Nikola V Mihaylov, et al.
Urology|February 13, 2018
Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free MethodHeather J Chalfin, Max Kates, Emma E van der Toom, et al.
Pageof 16

Showing results (91-100 of 157) with videos related to

Sort By:
Pageof 16
Archives of Pathology & Laboratory Medicine|July 1, 2026
Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease SitesSwati Bhardwaj, Eli Morris, Aditya Halthore, et al.
Clinical Genitourinary Cancer|December 28, 2020
Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective ExperienceJean Hoffman-Censits, Woonyoung Choi, Trinity J Bivalacqua, et al.
The Journal of Pathology. Clinical Research|February 19, 2025
Sarcomatoid areas of urothelial carcinoma are enriched for CD163-positive antigen-presenting cellsBurles A Johnson, Vamsi Parimi, Sonia Kamanda, et al.
The Journal of Urology|May 16, 2022
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder CancerMax Kates, Ahmed M Mansour, Donald L Lamm, et al.
World Journal of Urology|April 29, 2019
Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumorOudai Hassan, Belkiss Murati Amador, Kara A Lombardo, et al.
The Journal of Urology|March 25, 2026
UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION TrialSandip M Prasad, Dimitar Shishkov, Nikola Vladimirov Mihaylov, et al.
Urology Practice|November 11, 2025
Patient-Reported Outcomes Following UGN-102 Treatment in Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: An Analysis of 3 Clinical TrialsCharles C Peyton, Max Kates, Anagha Nadkarni, et al.
Urologic Oncology|October 25, 2016
Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomyMeera R Chappidi, Heather J Chalfin, Daniel J Johnson, et al.
The Journal of Urology|April 29, 2026
Reply by AuthorsSandip M Prasad, Dimitar Shishkov, Nikola V Mihaylov, et al.
Urology|February 13, 2018
Characterization of Urothelial Cancer Circulating Tumor Cells with a Novel Selection-Free MethodHeather J Chalfin, Max Kates, Emma E van der Toom, et al.
Pageof 16